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variable,	𝑆,	assuming	two	latent	classes	—	cases	(𝑌 = 1)	and	controls	(𝑌 = 0).		
Specifically,	we	assume	that	there	are	two	underlying	classes,	and	that	within	each	
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class,	𝑆	follows	a	binomial	distribution,	𝑃(𝑆 = 𝑠|𝐶 = 𝑐) = -./0𝑝2
/(1 − 𝑝2).4/	,	with	








let		𝜑(𝑐, 𝛼7, 𝛼6) = 𝑔(𝛼7 + 𝛼6𝑐),	where	the	parameters	𝜶 = (𝛼7, 𝛼6)	are	unknown	and	


























































































































S1	 S2	 S3	 PheProb	
Hyperlipidemia	
(ICD-9	272.x)	





HLA	DRB1	 <0.0001	 <0.0001	 <0.0001	 <0.0001	
PTPN22	 <0.0001	 <0.0001	 <0.0001	 0.0002	
* 𝑆N, is the thresholding approach where subjects are defined as cases if they have ≥t 
PheWAS codes		
	
	
	
Example	2:	Partners	Biobank	and	Rheumatoid	Arthritis	
Association	between	HLA	DRB1	or	PTPN22	and	billing	codes	for	RA	
Among	the	14,985	patients,	12%	had	at	least	1	diagnosis	code	for	RA.		Among	those	
with	at	least	1	billing	code,	the	median	number	of	billing	codes	was	14	and	the	
maximum	was	838.	The	results	of	the	genotype-phenotype	association	tests	are	
presented	in	Table	1.	The	p-values	for	the	association	between	RA	and	the	HLA	
DRB1	SNP	using	all	three	thresholding	methods	and	using	the	PheProb	approach	
were	less	than	0.0001;	the	p-value	for	the	association	between	the	PTPN22	and	RA	
was	less	than	0.0001	using	the	thresholding	methods	and	0.0002	using	the	PheProb	
approach.	
	
Validation	
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Because	the	p-values	for	all	methods	in	this	large	patient	population	were	small,	we	
sought	to	better	understand	how	well	the	standard	thresholding	methods	and	the	
PheProb	clustering	step	were	separating	cases	and	controls	by	comparing	accuracy	
metrics	in	a	group	of	546	patients	for	whom	true	RA	disease	status	was	known	
through	chart	review.		To	identify	cases	and	controls	from	the	PheProb	predicted	
probability	of	having	RA,	we	simply	dichotomized	it	at	its	mean.		The	results	are	
presented	in	Table	2.		The	prevalence	of	RA	in	the	validation	set	was	8.8%.	We	found	
that	PheProb	better	classified	individuals	without	the	disease	as	``controls''	(FPR	of	
0.01	vs.	0.06	for	S2),	and	that	the	individuals	classified	by	PheProb	as	cases	were	
more	likely	to	truly	have	RA	(precision	/	PPV	of	0.74	vs.	0.40	for	S2).		This	
improvement	in	PPV	came	at	a	cost	of	incorrectly	classifying	8%	of	true	disease	
cases	as	controls	(recall	of	0.92	vs.	1.00),	with	no	reduction	in	the	NPV	(the	chance	
that	an	individual	classified	as	control	is	truly	disease-free;	1.00	vs.	1.00).	In	
addition,	we	found	that	PheProb	outperformed	S2	in	regards	to	precision	and	recall	
(F1	score	of	0.83	vs.	0.57,	P	<0.0001).	
	
	
Table	2.	Comparison	of	accuracy	measures	of	case-control	identification	for	RA	
comparing	the	standard	thresholding	method	𝑆O*	with	PheProb	against	the	true	
phenotype	as	defined	by	chart	review.	
	
	 S2	 PheProb	
precision	/	PPV	 0.40	 0.74	
NPV	 1.00	 1.00	
recall	 1.00	 0.92	
FPR	 0.06	 0.01	
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F1	score	 0.57	 0.83	
*	𝑆O,	subjects	with	≥2	PheWAS	codes	are	defined	as	cases	
PPV	=	positive	predictive	value;	NPV	=	negative	predictive	value;	FPR	=	false	
positive	rate.	
	
	
	
	
DISCUSSION	
The	PheProb	approach	provides	a	high-throughput,	unsupervised	method	for	
phenotyping	using	existing	codified	data	without	requiring	labor	intensive	chart	
review	for	gold	standard	labels.			In	this	study,	we	observed	that	PheProb,	which	
converts	the	number	of	diagnosis	codes	into	a	probability	for	a	phenotype,	provided	
more	power	for	genetic	association	studies	using	EHR	data	compared	to	standard	
PheWAS	thresholding	approaches,	while	maintaining	the	feasibility	of	standard	
approaches	by	using	only	structured	data.		The	thresholding	approach	is	limited	
because	of	the	varying	accuracy	of	diagnosis	codes,	and	PheProb	addresses	this	
challenge	by	using	the	diagnosis	code	counts	to	separate	the	patients	into	two	latent	
underlying	classes	—	case	and	controls	—in	a	data-adaptive	way	while	accounting	
for	total	health	care	utilization.		This	approach	in	effect	normalizes	the	accuracy	of	
the	codes.	
	 PheWASs	using	the	thresholding	method	have	been	conducted	with	different	
threshold	choices,	and	there	does	not	appear	to	be	a	consensus	on	a	best	threshold	
[9,10,12,13,16–20,23,24].		Increasing	the	number	of	diagnosis	codes	used	to	define	
cases	tends	to	increase	the	PPV,	or	the	chance	that	those	included	as	cases	do	in	fact	
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have	the	disease.		However,	particularly	for	uncommon	diseases,	this	may	result	in	a	
loss	of	statistical	power	when	testing	for	the	SNP-disease	association,	since	it	
reduces	the	number	of	individuals	included	in	the	test.		We	observed	loss	of	power	
with	higher	thresholding	in	the	simulations	with	an	uncommon	phenotype	
(prevalence=5%):	with	SNP	OR=1.1,	the	power	of	S2	was	6.4%	while	the	power	of	S3	
was	5.4%.			In	this	scenario,	the	benefit	of	improving	the	PPV	of	the	case	definition	
by	requiring	more	billing	codes	is	likely	outweighed	by	the	power	lost	by	losing	
some	true	disease	cases.				Converting	a	quantitative	variable	such	as	the	billing	code	
count	to	a	binary	variable	can	also	result	in	loss	of	information	even	if	a	best	
threshold	were	determined,	since	more	codes	likely	reflect	a	more	certain	disease	
status	or	greater	disease	severity.		The	PheProb	method	avoids	many	of	these	issues	
by	using	the	billing	code	counts	directly	as	a	quantitative	variable,	letting	the	data	
drive	the	clustering	into	cases	and	controls.	
The	thresholding	method	also	does	not	take	into	account	differing	levels	of	
health	care	utilization.	We	believe	incorporating	total	health	care	utilization	into	
PheProb,	as	quantified	by	the	total	number	of	billing	codes,	enhances	performance	
because	the	amount	of	utilization	can	vary	dramatically	across	patients.		Total	
health	care	utilization	can	affect	the	informativeness	of	certain	billing	codes,	
particularly	for	diseases	that	may	have	many	diagnostic	tests.		For	example,	an	
individual	with	10	total	billing	codes,	5	of	them	for	hyperlipidemia,	may	be	more	
likely	to	be	a	case	than	an	individual	with	1000	total	codes,	5	of	which	are	for	
hyperlipidemia.	
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	 In	the	PheProb	approach,	the	actual	test	for	association	is	performed	
between	the	SNP	and	the	estimated	probability	of	having	the	phenotype.		This	
eliminates	the	need	to	select	a	threshold	to	define	case-control	status,	and	carries	
forward	into	the	association	test	some	information	about	classification	uncertainty	
as	encoded	in	the	estimated	probability	of	disease.		Individuals	with	many	billing	
codes	are	assigned	high	probability	of	having	the	disease;	those	with	no	codes	are	
assigned	low	probability;	and	those	with	a	moderate	number	can	have	a	probability	
in	the	middle,	where	"moderate"	is	determined	in	the	data-driven	clustering	and	
will	be	slightly	different	for	different	phenotypes.		Retaining	this	algorithmic	
classification	uncertainty	rather	than	thresholding	has	been	shown	to	improve	
power	in	other	EHR	settings	[33].	
	 In	the	example	of	RA,	where	a	gold	standard	was	available	for	comparison,	
we	found	that	the	probability	of	being	a	case	from	the	PheProb	approach	better	
distinguished	cases	and	controls	than	the	standard	thresholding	method.		That	is,	
identifying	cases	as	patients	with	above	average	PheProb	probability	was	a	more	
accurate	case	definition	than	identifying	cases	as	patients	with	more	than	2	ICD-9	
code	counts	(F1	score	of	0.83	vs.	0.57,	p<0.0001).		This	is	likely	because	the	
clustering	step	seeks	to	separate	cases	and	controls	in	a	data-adaptive	way,	and	uses	
both	information	in	the	disease-relevant	billing	codes	and	the	total	billing	codes	in	
the	clustering,	rather	than	using	a	fixed	threshold	on	just	the	relevant	billing	codes.	
	 As	detailed	here,	many	aspects	of	the	PheProb	approach	were	designed	to	
improve	genetic	association	test	power:	leveraging	the	diagnosis	code	counts	as	a	
quantitative	variable	instead	of	dichotomizing	it;	integrating	healthcare	utilization	
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in	the	structure	of	the	mixture	model;	and	using	the	continuous	model-predicted	
probability	of	being	a	disease	case	as	an	outcome	instead	of	thresholding	it	to	
identify	case-control	status.		Unfortunately,	it	is	difficult	to	disentangle	the	impacts	
on	power	of	each	of	these	aspects.		For	example,	a	patient's	healthcare	utilization	𝐶	
enters	the	method	as	a	parameter	in	the	binomial	mixture	model;	avoiding	reliance	
on	𝐶	would	necessitate	using	a	different	parametric	mixture	model,	but	
performance	differences	due	to	the	change	in	model	and	the	reliance	on	𝐶	cannot	be	
rigorously	disentangled.		Similarly,	we	propose	using	the	model-predicted	
probability	rather	than	a	dichotomous	outcome	in	the	genetic	association	test;	this	
is	because	we	feel	that	the	probability	better	carries	forward	phenotyping	
uncertainty	into	the	test,	but	it	is	also	not	obvious	how	best	to	dichotomize	that	
predicted	probability	into	a	case-control	outcome	in	the	absence	of	any	gold-
standard	outcome	data,	and	whether	patients	with	mid-level	predicted	probability	
should	be	excluded	in	such	a	dichotomization.	
With	no	additional	covariates	(such	as	age	and	gender),	our	genotype-
phenotype	test	is	essentially	model-free	—	it	is	fundamentally	testing	whether	the	
genotype	and	phenotype	are	statistically	independent.		Thus,	it	is	a	valid	test	across	
a	wide	range	of	true	disease-genotype	models.		With	additional	covariates,	our	
model	is	still	valid	across	a	wide	range	of	true	disease-genotype	models	so	long	as	
the	genotype	is	independent	of	those	covariates.		Relaxing	this	assumption	to	
produce	an	even	more	robust	test	is	a	direction	of	future	research.	
The	PheProb	method	is	designed	to	increase	power	for	studies	which	rely	on	
(or	are	limited	to	using)	ICD	codes	for	phenotyping,	with	direct	applications	to	
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PheWAS.		It	was	designed	for	studies	screening	across	hundreds	to	thousands	of	
phenotypes,	where	creating	individual	highly	accurate	algorithms	for	each	
phenotype	is	not	feasible.		While	it	may	serve	as	a	starting	point	for	investigators	
interested	in	detailed	studies	on	a	specific	phenotype,	it	was	not	designed	for	this	
purpose.	
Institutions	have	different	EHR	systems	and	different	approaches	to	using	
those	systems.	As	a	result,	phenotyping	methods	typically	have	varying	
performance	across	institutions.		This	variability	is	especially	notable	when	
phenotyping	is	based	only	on	thresholded	diagnosis	codes.		For	example,	using	at	
least	one	code	for	RA	to	identify	cases	was	shown	to	have	a	PPV	of	22%,	26%,	and	
49%	across	three	institutions,	while	using	at	least	three	codes	was	shown	to	have	a	
PPV	of	55%,	42%,	and	73%	across	the	same	three	institutions	[21].		This	highlights	
another	difficulty	of	existing	PheWAS	methods	based	on	thresholding	—	even	for	a	
single	disease,	the	best	threshold	for	defining	a	case	may	vary	across	institutions.		A	
method	like	PheProb	that	has	the	potential	to	adapt	to	the	underlying	distribution	of	
diagnosis	codes	at	an	institution	may	be	effective	in	the	face	of	this	heterogeneity,	
and	further	evaluating	PheProb's	performance	and	robustness	across	healthcare	
systems	is	a	direction	of	future	research.	
	
CONCLUSION	
Compared	to	the	standard	PheWAS	approach	which	defines	phenotypes	using	a	
certain	number	of	diagnosis	codes,	the	PheProb	approach	provides	more	power	to	
study	genotype-phenotype	associations	by	retaining	information	on	the	count	of	
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billing	codes	defining	the	phenotype	normalized	by	health	care	utilization	
information,	and	providing	a	probability	of	a	phenotype	rather	than	a	binary	case-
control	status	for	association	testing.		In	sum,	PheProb	is	a	scalable	method	for	rapid	
unsupervised	phenotyping	with	direct	applications	for	PheWAS	and	large	scale	
EHR-biorepository	genetic	association	studies.			
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FIGURE	LEGENDS	
Figure	1.		Workflow	of	the	PheProb	method.		True	disease	status	of	patients	is	
unknown;	instead,	the	number	of	billing	codes	for	each	disease	is	observed.		The	
PheProb	method	clusters	individuals	based	on	billing	codes,	and	tests	for	an	
association	between	a	genetic	marker	such	as	a	SNP	and	the	clustering-based	
probability	of	being	a	case.	
Figure	2.	Comparison	of	power	to	detect	an	association	between	a	SNP	and	a	
phenotype	(a	disease)	when	only	S,	the	count	of	billing	codes,	is	observed.		The	
standard	approaches	of	thresholding	S	and	identifying	disease	cases	as	individuals	
with	more	than	t	billing	codes	are	indicated	by	St,	for	t=1,2,3.		Our	proposed	method	
is	indicated	by	PheProb.		A	benchmark	method	is	also	shown:	true-Y,	which	uses	the	
true	disease	status	as	the	outcome.		Simulation	settings	vary	the	prevalence	and	the	
strength	of	the	association	of	interest	between	disease	status	and	the	SNP:	OR=1.1	
for	a	weak	relationship	and	OR=1.35	for	a	moderate	relationship.	
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